Cancer News and Research

Latest Cancer News and Research

Zevalin radioimmunotherapy drug approved for treating non-Hodgkin's lymphoma

SNM applauds the U.S. Food and Drug Administration's (FDA) recent decision to approve the radioimmunotherapy (RIT) drug, Zevalin, as a front-line treatment of non-Hodgkin's lymphoma (NHL).

11 Sep 2009

Medicare reimbursement cuts will affect cancer care system

The Community Oncology Alliance (COA), a national non-profit organization that represents oncologists and other cancer care providers, strongly opposes cuts in Medicare reimbursement for cancer care outlined by the Centers for Medicare & Medicaid Services (CMS).

11 Sep 2009

eChIP genetic technique developed to examine FA proteins with DNA crosslinks

While Fanconi anemia (FA) is a rare and dangerous disease, new laboratory research at The University of Texas M. D. Anderson Cancer Center shows it may lead researchers toward clues in more common diseases, including highly hereditary types of breast cancer.

11 Sep 2009

New Drug Application for trabectedin approved by the FDA

Centocor Ortho Biotech Products, L.P. today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for trabectedin when administered in combination with DOXIL(R) (doxorubicin HCI liposome injection) for the treatment of women with relapsed ovarian cancer.

11 Sep 2009

Fau and MELK genes may help improve breast cancer diagnosis and treatment

Researchers at Keele University have identified two genes which may help improve the diagnosis and treatment of breast cancer patients.

11 Sep 2009

Blood collection professionals honored as part of the 5th Annual Blood Collectors Week

Blood collection professionals will be recognized in communities worldwide September 13-19, 2009, as part of the 5th Annual Blood Collectors Week, sponsored jointly by Fenwal, Inc. and AABB (formerly known as the American Association of Blood Banks). During the week, blood centers across the country will host celebrations, often with local government officials, to recognize their staffs and donors.

11 Sep 2009

TrKA and CCM2 combination results in pediatric tumour regression

Why are some pediatric cancers able to spontaneously regress? Prof. Michael Fainzilber and his team of the Weizmann Institute's Biological Chemistry Department seem to have unexpectedly found part of the answer. Further research towards a better understanding of the mechanism of action might hopefully lead, in the future, to the development of drugs that will be able to induce regression of certain tumors.

10 Sep 2009

CytRx granted patent for molecular chaperone amplifier drug candidate

CytRx Corporation, a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced that it has been granted a key patent by the European Patent Office that covers through 2024 the use of its orally available molecular chaperone amplifier drug candidate arimoclomol for the treatment or prevention of neurodegenerative diseases of the central nervous system (CNS).

10 Sep 2009

FDA approves Supplemental New Drug Application for DOXIL

Centocor Ortho Biotech Products, L.P. today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its Supplemental New Drug Application (sNDA) for DOXIL (doxorubicin HCI liposome injection) in combination with docetaxel for the treatment of women with locally advanced and metastatic breast cancer.

10 Sep 2009

Vitro Diagnostics' novel stem cell technology for cancer treatment

Vitro Diagnostics, Inc., dba Vitro Biopharma, announced advances in its adult stem cell products and technology with application to cell-based therapy of cancer. With the passing of Senator Edward Kennedy from brain cancer, we are reminded of such aggressive cancers without effective treatment.

10 Sep 2009

Endothelin research update to be presented at APS' 11th International Conference

Recent research to block the effects of endothelin, a powerful substance that constricts blood vessels and stimulates cell growth, has led to successful treatment of pulmonary arterial hypertension and provides hope for treating other chronic diseases.

10 Sep 2009

Esperance Pharmaceuticals begins human clinical trials of its EP-100 cancer therapeutic candidate

Drug discovery and development company Esperance Pharmaceuticals today announced that it has begun enrollment and dosing of patients in a Phase 1 study of EP-100 in patients with advanced solid tumors. EP-100, the lead candidate from Esperance's Cationic Lytic Peptide (CLYP(TM)) platform technology, is a targeted membrane-disrupting peptide (tMDP) designed to seek and destroy cancer cells that over-express luteinizing hormone releasing hormone (LHRH) receptors on their surfaces.

10 Sep 2009

UCSB researchers use lasers to deliver drugs into cancer cells

Researchers at UC Santa Barbara have developed a new way to deliver drugs into cancer cells by exposing them briefly to a non-harmful laser. Their results are published in a recent article in ACS Nano, a journal of the American Chemical Society.

10 Sep 2009

Acceleron's Phase 1 trial of ACE-031 reveals its potential in treating neuromuscular diseases

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, and muscle, today announced preliminary results from the ACE-031 Phase 1 single dose clinical trial demonstrating that ACE-031 increased lean body mass and muscle volume. The results from this randomized, placebo-controlled study were presented at the 14th International Congress of the World Muscle Society in Geneva, Switzerland.

10 Sep 2009

GI Company's Phase II study demonstrates safety of rhITF oral spray formulation

Published today, as an original investigation, in the peer-reviewed Journal of Clinical Oncology, are statistically significant Phase II clinical results of The GI Company's lead clinical compound, rhITF (recombinant human Intestinal Trefoil Factor) oral spray. The article is titled, "A Phase II, Randomized, Double-blind, Placebo-Controlled Study of rhITF Oral Spray for Prevention of Oral Mucositis in Colorectal Cancer Patients Receiving 5-Fluorouracil-based Chemotherapy."

10 Sep 2009

PinnacleCare and Champions Biotechnology collaborate to offer personalized oncology services worldwide

Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company whose personalized oncology services division assists physicians by providing personalized treatment options for their cancer patients, has entered into a collaboration agreement with PinnacleCare, the pioneer and the leading private health advisory company in the world.

10 Sep 2009

FDA approves Ascenta's IND for AT-406 multi-IAP antagonist

Ascenta Therapeutics announced today that following the approval by the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) Application for AT-406, an orally-active, small molecule, multi-IAP antagonist, the company will initiate a Phase I clinical trial in patients with advanced cancer during the fourth quarter of 2009.

10 Sep 2009

GENova Biotherapeutics files patent to combat breast cancer

(OTCBB: GVBP.OB) - GENova Biotherapeutics, Inc., ("GENova"), a biotechnology company that identifies, acquires, and develops novel drug targets that disrupt the advance of life-threatening diseases, today announced it has filed a patent for a potential blockbuster drug target that combats breast cancer.

10 Sep 2009

Protox' Phase 2 study of PRX302 for treating BPH provides positive results

Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins, today announced positive 12 month data from its open-label Phase 2 study of PRX302 in males with moderate to severe benign prostatic hyperplasia (BPH). The study results indicate that those patients who received an optimal dose of PRX302 continued to demonstrate significant symptomatic relief at 12 months following a single treatment.

10 Sep 2009

Third-quarter fiscal 2009 results announced by MDS

MDS Inc. (TSX: MDS; NYSE: MDZ), a leading provider of products and services to the global life sciences markets, today reported financial results for the three-month period ended July 31, 2009. MDS reported total revenue of $199 million, a net loss of $62 million and a loss per share of $0.51 for the third quarter of 2009, compared with $252 million in total revenue, a net loss of $10 million and a loss per share of $0.08 for the same period last year.

10 Sep 2009